Rasmus Mortensen

Head of TB Vaccine Research

Statens Serum Institut

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (7)

Martin Kongsbak-Wismann

Københavns Universitet

DENMARK

View details

Tu Hu

Statens Serum Institut

DENMARK

View details

Nicolai Arildsen

Københavns Universitet

DENMARK

View details

Simon van Haren

Assistant Professor of Pediatrics

Harvard University

UNITED STATES

View details

Gregers Jungersen

Research Professor, Head of Section for Gastrointestinal Vaccine Research

Statens Serum Institut

DENMARK

View details

Corina S. Rueegg

NORWAY

View details

Sara Marie Solbak

Københavns Universitet

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rasmus Mortensen

Research Interests

Explore related searches

Contact this professor

Articles (10)

Author Correction: Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice

Author Correction: Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells

Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells

A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG.

Reduced vitamin D-induced cathelicidin production and killing of Mycobacterium tuberculosis in macrophages from a patient with a non-functional vitamin D receptor

A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients

A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin.

Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.

In Vivo Antigen Expression Regulates CD4 T Cell Differentiation and Vaccine Efficacy against Mycobacterium tuberculosis Infection.

In Vivo Antigen Expression Regulates CD4 T Cell Differentiation and Vaccine Efficacy against Mycobacterium tuberculosis Infection

Collaborators (7)

Martin Kongsbak-Wismann

Tu Hu

Nicolai Arildsen

Simon van Haren

Gregers Jungersen

Corina S. Rueegg

Sara Marie Solbak

Make your next move.